NECT Is Next: Implementing the New Drug Combination Therapy for <i>Trypanosoma brucei gambiense</i> Sleeping Sickness.

Abstract

This Viewpoint article briefly describes: the development and advantages of nifurtimox-eflornithine combination therapy (NECT) for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness; recent and ongoing developments, and current and future challenges, in its implementation in the field; and its limitations. It is concluded that efficient NECT delivery must be sustained to ensure that all patients can benefit, and that better drugs and diagnostics are still needed to control the disease.

Citation

PLoS Neglected Tropical Diseases (2010) 4 (5) e720 [doi:10.1371/journal.pntd.0000720].

NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness.

Help us improve GOV.UK

Don’t include personal or financial information, eg your National Insurance number or credit card details.